Stereotactic Body Radiotherapy for Genitourinary

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Princess Margaret Cancer Centre, Toronto, CanadaGenitourinary+2 MoreStereotactic Body Radiotherapy - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is investigating whether using high doses of focused radiation (SBRT) to treat oligo-progression (a subset of cancer cells that develop heterogeneity and resistant clones while receiving systemic therapy) is effective.

Eligible Conditions
  • Genitourinary
  • Metastatic Breast Cancer
  • Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Stereotactic body radiotherapy
1
Standard dose SBRT
1
Stereotactic body radiotherapy (SBRT)

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 24 month period

24 month period
Malignant Neoplasms
Feasibility of SBRT in OP malignancies
Safety of SBRT in OP malignancies

Trial Safety

Safety Progress

1 of 3

Similar Trials

2
Stereotactic body radiotherapy
2
Standard dose SBRT
2
Stereotactic body radiotherapy (SBRT)

Side Effects for

SBRT With Gem
15%ulcer
10%vomiting
5%Perforation
5%pain
This histogram enumerates side effects from a completed 2008 Phase 2 trial (NCT00350142) in the SBRT With Gem ARM group. Side effects include: ulcer with 15%, vomiting with 10%, Perforation with 5%, pain with 5%.

Trial Design

3 Treatment Groups

Oligo-Progression; GU
1 of 3
Oligo-metastatic Breast Cancer
1 of 3
Intervention
1 of 3

Experimental Treatment

100 Total Participants · 3 Treatment Groups

Primary Treatment: Stereotactic Body Radiotherapy · No Placebo Group · N/A

Oligo-Progression; GU
Radiation
Experimental Group · 1 Intervention: Stereotactic Body Radiotherapy · Intervention Types: Radiation
Oligo-metastatic Breast Cancer
Radiation
Experimental Group · 1 Intervention: Stereotactic Body Radiotherapy · Intervention Types: Radiation
Intervention
Radiation
Experimental Group · 1 Intervention: Stereotactic Body Radiotherapy · Intervention Types: Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Body Radiotherapy
2017
Completed Phase 2
~220

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 month period

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,386 Previous Clinical Trials
471,879 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have 5 or fewer areas of cancer growth in your breast, prostate, bladder, or kidney that can be treated with radiotherapy, surgery, or other ablative treatments.
References

Frequently Asked Questions

Are there still opportunities for patients to register in this trial?

"Affirmative. Clinicaltrials.gov's records demonstrate that, from 9/11/2019 to 10/6/2022, this clinical trial is actively recruiting 80 participants at a single site." - Anonymous Online Contributor

Unverified Answer

How many individuals are being recruited to participate in this research?

"Affirmative. According to the information sourced from clinicaltrials.gov, this trial is recruiting participants and was first posted on September 11th 2019 with its most recent update occurring October 6th 2022. 80 patients must be enrolled at a single location for the study to proceed." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top